Brii Biosciences Narrows 2025 Loss as Costs Fall and Revenue Emerges

An announcement from Brii Biosciences Limited ( (HK:2137) ) is now available.

Brii Biosciences reported its annual results for the year ended December 31, 2025, showing an emerging revenue base and a significantly narrowed loss. The company’s bank deposits and cash and cash equivalents declined 19.6% to RMB1,941.0 million, mainly due to funding daily operations, research and development activities, and the acquisition of BRII-179-related assets.

Revenue reached RMB18.6 million from zero a year earlier, driven by an upfront payment from an intellectual property license and technology transfer agreement with Joincare Group. Other income fell 51.3% to RMB68.8 million on lower bank interest income and reduced government grants, reflecting a less favorable interest rate environment and fewer subsidies.

Research and development expenses dropped 14.8% to RMB212.9 million as the company prioritized its portfolio, cut third-party contracting costs, and optimized senior management compensation, while still increasing investment in early-stage discovery programs. Administrative expenses declined 28.5% to RMB109.5 million, helped by lower employee costs, reduced professional fees, and broader organizational optimization and cost controls.

Overall loss for the year narrowed by 56.3% to RMB224.1 million, largely due to reduced fair value losses on equity investments and lower impairment charges, alongside decreased operating expenses. The results indicate improving operational efficiency and financial discipline, suggesting a more sustainable cost base as Brii Biosciences advances its pipeline and seeks to strengthen its position in the biopharmaceutical sector.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

More about Brii Biosciences Limited

Brii Biosciences Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies, with a particular emphasis on infectious diseases and related conditions. Listed on the Hong Kong Stock Exchange, the company pursues a pipeline-driven strategy and invests in early-stage discovery programs to support long-term growth in its core therapeutic areas.

Average Trading Volume: 1,257,314

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.1B

See more insights into 2137 stock on TipRanks’ Stock Analysis page.